Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Tavotek Bio Raises $20 Million-plus for Novel US-China Antibodies

publication date: Mar 22, 2021

Tavotek Biotherapeutics, a Philadelphia-Suzhou biotech, raised more than $20 million in Round A1 and Round A2 financings over the last two months. Tavotek said it would use the capital for CMC production and IND filings of its three lead antibody drugs. It will also expand its bispecific/multispecific antibody pipelines and intracellular peptide (MIP) programs for autoimmune and oncology indications. In 2019, Tavotek was founded with an initial round from Apricot Capital. Tavotek has R&D operations in the Philadelphia area and Suzhou. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital